Crescent Biopharma, Inc.
CBIOHealthcare|Biotechnology|US
$13.54
+0.60 (+4.64%)
DCF Value
$20.78
Tangible Book / Share
$5.35
Cash / Share
$5.62
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07335497 CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Locally Advanced / Metastatic Solid Tumors | P1P2 | Recruiting | 540 | Open-label | CR-001, Paclitaxel, trifluridine and tipiracil, Pemetrexed, Carboplatin, Oxaliplatin, Gemcitabin, Cisplatin, Capecitabine, FOLFOX |
| NCT07909031 CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ | P1P2 | Recruiting | 219 | Open-label | CR-002 |